STOCK TITAN

GSK (NYSE: GSK) details April 2026 total voting rights and share capital

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

GSK plc reported its share capital and voting rights as of 30 April 2026. The company had 4,316,202,660 ordinary shares of 31¼ pence each in issue, including 261,378,286 shares held in treasury. This leaves a total of 4,054,824,374 voting rights for shareholder disclosure calculations.

Positive

  • None.

Negative

  • None.
Issued share capital 4,316,202,660 shares Ordinary shares of 31¼ pence each as of 30 April 2026
Treasury shares 261,378,286 shares Ordinary shares held in treasury as of 30 April 2026
Total voting rights 4,054,824,374 Voting rights in GSK plc as of 30 April 2026
Nominal value per share 31¼ pence Par value of each ordinary share
Reference rule DTR 5.6.1R FCA Disclosure Guidance and Transparency Rule governing voting rights notifications
Total Voting Rights financial
"Therefore, the total number of voting rights in the Company is 4,054,824,374."
The total voting rights number is the count of shares that carry the right to vote at a company’s shareholder meetings, reflecting how much voting power exists in the market. Investors use it to understand control and influence—like knowing how many votes are in play when measuring ownership stakes, calculating a shareholder’s voting percentage, or assessing how easy it would be for a holder to sway decisions.
treasury financial
"of which 261,378,286 Ordinary Shares were held in Treasury."
The treasury is the department or area within a government or organization responsible for managing its money, finances, and financial strategies. It handles tasks like collecting revenue, paying bills, and planning for future financial needs, much like a household manages its budget. For investors, understanding the treasury is important because it influences interest rates, government spending, and overall economic stability.
Disclosure Guidance and Transparency Rule 5.6.1R regulatory
"In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R"
Form 20-F regulatory
"whether the registrant files or will file annual reports under cover of Form 20-F"
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
foreign private issuer regulatory
"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of May 2026
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Issued: 1 May 2026, London UK
 
Total Voting Rights
   
 
 
 
In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the 'Company') hereby notifies the market of the following:
 
The Company's issued share capital as at 30 April 2026 consisted of 4,316,202,660 shares of 31 ¼ pence each ('Ordinary Shares'), of which 261,378,286 Ordinary Shares were held in Treasury.
 
Therefore, the total number of voting rights in the Company is 4,054,824,374. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
 
Notifications may be sent to company.secretary@gsk.com.
 
 
V A Whyte
Company Secretary
 
1 May 2026
 
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
 
Registered in England & Wales:
No. 3888792
  
Registered Office:
79 New Oxford Street
London
WC1A 1DG
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: May 01, 2026
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc

FAQ

What total voting rights did GSK (GSK) report as of 30 April 2026?

GSK reported a total of 4,054,824,374 voting rights as of 30 April 2026. Shareholders can use this figure as the denominator when calculating whether they must notify holdings under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

How many GSK (GSK) shares were in issue and held in treasury?

GSK’s issued share capital consisted of 4,316,202,660 ordinary shares, of which 261,378,286 shares were held in treasury. Only shares not held in treasury carry voting rights, forming the basis for the total voting rights calculation disclosed.

What type of shares make up GSK (GSK) share capital in this filing?

GSK’s share capital is made up of ordinary shares of 31¼ pence each. These ordinary shares represent the company’s equity listed for investors and, excluding treasury shares, each typically carries one voting right used in shareholder meetings and disclosure calculations.

Why did GSK (GSK) publish total voting rights information?

GSK published total voting rights information to comply with FCA Disclosure Guidance and Transparency Rule 5.6.1R. The disclosed voting rights figure helps shareholders determine when they must notify the company and regulators about their interests or changes in their shareholdings.

Which SEC annual report form does GSK (GSK) use as a foreign issuer?

GSK files its annual reports under Form 20-F as a foreign private issuer. Form 20-F is the standard SEC reporting format for non-U.S. companies whose securities trade in the United States, aligning with U.S. disclosure and accounting requirements.

How can investors contact GSK (GSK) about disclosure notifications?

Investors can send disclosure notifications to GSK via company.secretary@gsk.com. This email contact is provided for shareholders calculating positions against the published voting rights figure and needing to report interests under UK Financial Conduct Authority transparency rules.